Program Description
Myelofibrosis, a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms, presents substantial challenges in both clinical management and health system resource utilization. Despite the availability of Janus kinase inhibitors (JAKis), disease progression, anemia, and thrombocytopenia remain persistent barriers to optimal outcomes. In recent years, there has been a push for individualized treatment sequencing strategies and the integration of emerging disease-modifying agents. The treatment landscape has expanded beyond JAKi monotherapy to include ruxolitinib-based combinations and agents with novel mechanisms of action and the potential to not only reduce spleen size and improve symptoms but also modify the disease trajectory. Oncology pharmacists in managed care roles must be ready to interpret emerging clinical trial data and assess how these novel therapies can be integrated into practice. This program presents the latest evidence on guideline-directed therapy selection, molecular risk stratification, and real-world data to inform formulary and coverage decisions. Participants will explore strategies to optimize transitions between therapies, manage treatment-related anemia, and address the economic and quality-of-life burden associated with myelofibrosis. Expert speakers will break down clinical trial evidence, current guidelines, and value-based care principles, equipping pharmacists to support patient-centered outcomes and ensure the appropriate, cost-effective use of novel and established therapies in myelofibrosis.
Target audience: Managed Care Pharmacist, Oncology Pharmacist
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the latest clinical evidence, guideline updates, and emerging therapeutic strategies in myelofibrosis to inform evidence-based formulary decisions and ensure the appropriate use of available drug therapies.
- Apply best practices for sequencing and transitioning patients with myelofibrosis to subsequent therapies following progression or intolerance, with attention to safety, efficacy, and supportive care considerations.
- Examine the clinical and economic burden of myelofibrosis and strategies to optimize patient outcomes and value-based care through integration of novel therapies and real-world evidence.